Corrigendum to “Effectiveness and Safety of Oral Anticoagulants in Adults with Non-valvular Atrial Fibrillation Patients and Concomitant Coronary/Peripheral Artery Disease” American Journal of Medicine 131:09 (2018): 1074-1085.e4
There were 33,269 apixaban-warfarin, 9,345 dabigatran-warfarin, and 42,156 rivaroxaban-warfarin matched pairs, with a median follow-up of 4-5 months. Compared with warfarin, apixaban was associated with lower rates of stroke/systemic embolism (hazard ratio [HR] 0.52; 95% confidence interval [95% CI]...
Gespeichert in:
| Veröffentlicht in: | The American journal of medicine 2020-10, Vol.133 (10), p.1229-1238 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1238 |
|---|---|
| container_issue | 10 |
| container_start_page | 1229 |
| container_title | The American journal of medicine |
| container_volume | 133 |
| creator | Lopes, Renato D. Steffel, Jan Di Fusco, Manuela Keshishian, Allison Luo, Xuemei Li, Xiaoyan Masseria, Cristina Hamilton, Melissa Friend, Keith Gupta, Kiran Mardekian, Jack Pan, Xianying Baser, Onur Jones, W. Schuyler |
| description | There were 33,269 apixaban-warfarin, 9,345 dabigatran-warfarin, and 42,156 rivaroxaban-warfarin matched pairs, with a median follow-up of 4-5 months. Compared with warfarin, apixaban was associated with lower rates of stroke/systemic embolism (hazard ratio [HR] 0.52; 95% confidence interval [95% CI], 0.43-0.62), major bleeding (HR 0.60; 95% CI, 0.55-0.66) and stroke/myocardial infarction/all-cause mortality (HR 0.70; 95%CI, 0.66-0.74); dabigatran was associated with lower rates of major bleeding (HR: 0.73; 95% CI, 0.62-0.85); dabigatran and rivaroxaban were associated with lower rates of stroke/myocardial infarction/all-cause mortality (HR 0.77; 95% CI, 0.69-0.86 and HR 0.81; 95% CI, 0.77-0.85, respectively). Rivaroxaban was associated with a lower rate of stroke/systemic embolism (HR 0.61; 95% CI, 0.53-0.71) and a higher rate of major bleeding (HR 1.10; 95%CI, 1.03-1.18) versus warfarin. |
| doi_str_mv | 10.1016/j.amjmed.2020.06.003 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2432431413</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002934320305362</els_id><sourcerecordid>2432431413</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1793-784bff14cc5867397d3b17214f46f15f98d6ca4d2d3b96b6c1da15244e57e3623</originalsourceid><addsrcrecordid>eNp9UU1v1DAQjRBILIV_wMHHckhqx46T9IC02rZ8qNBKwNnyOuPWq8RebGfR3vpD4M_1xr9gluWMZGlmPPOePe8VxWtGK0aZPNtUetpMMFQ1rWlFZUUpf1IsWNM0Zctk_bRYUErrsueCPy9epLTBkvaNXBS_VyFGdwd-mCeSA3l8-HlpLZjsduAhJaL9QL5oC3lPgiU3UY9k6bMzQd_No_Y5EefJcphHzH64fE8-B1_u9LjDbiTLHB0irtw6unHU2QVPbjHAAXigXgVvwuQyMmEeg9dxf3YL0W3v4e9bMUPckwuXQCd4fPhFlhN2jfbkY5ijxxH81icYnHEeCOPsnPbktKase3NOGG1FyWjXVCBeFs-sHhO8-hdPim9Xl19X78vrm3cfVsvr0rC252XbibW1TBjTdLLlfTvwNWtrJqyQljW27wZptBhqvO_lWho2aNbUQkDTApc1PylOj7zbGL7PkLKaXDKA23sIc1K14HiYYBxHxXHUxJBSBKu20U2ogGJUHZxVG3V0Vh2cVVQqdBZhb48wwDV2DqJKBhU1KEJE59QQ3P8J_gCuTrDN</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2432431413</pqid></control><display><type>article</type><title>Corrigendum to “Effectiveness and Safety of Oral Anticoagulants in Adults with Non-valvular Atrial Fibrillation Patients and Concomitant Coronary/Peripheral Artery Disease” American Journal of Medicine 131:09 (2018): 1074-1085.e4</title><source>Access via ScienceDirect (Elsevier)</source><creator>Lopes, Renato D. ; Steffel, Jan ; Di Fusco, Manuela ; Keshishian, Allison ; Luo, Xuemei ; Li, Xiaoyan ; Masseria, Cristina ; Hamilton, Melissa ; Friend, Keith ; Gupta, Kiran ; Mardekian, Jack ; Pan, Xianying ; Baser, Onur ; Jones, W. Schuyler</creator><creatorcontrib>Lopes, Renato D. ; Steffel, Jan ; Di Fusco, Manuela ; Keshishian, Allison ; Luo, Xuemei ; Li, Xiaoyan ; Masseria, Cristina ; Hamilton, Melissa ; Friend, Keith ; Gupta, Kiran ; Mardekian, Jack ; Pan, Xianying ; Baser, Onur ; Jones, W. Schuyler</creatorcontrib><description>There were 33,269 apixaban-warfarin, 9,345 dabigatran-warfarin, and 42,156 rivaroxaban-warfarin matched pairs, with a median follow-up of 4-5 months. Compared with warfarin, apixaban was associated with lower rates of stroke/systemic embolism (hazard ratio [HR] 0.52; 95% confidence interval [95% CI], 0.43-0.62), major bleeding (HR 0.60; 95% CI, 0.55-0.66) and stroke/myocardial infarction/all-cause mortality (HR 0.70; 95%CI, 0.66-0.74); dabigatran was associated with lower rates of major bleeding (HR: 0.73; 95% CI, 0.62-0.85); dabigatran and rivaroxaban were associated with lower rates of stroke/myocardial infarction/all-cause mortality (HR 0.77; 95% CI, 0.69-0.86 and HR 0.81; 95% CI, 0.77-0.85, respectively). Rivaroxaban was associated with a lower rate of stroke/systemic embolism (HR 0.61; 95% CI, 0.53-0.71) and a higher rate of major bleeding (HR 1.10; 95%CI, 1.03-1.18) versus warfarin.</description><identifier>ISSN: 0002-9343</identifier><identifier>EISSN: 1555-7162</identifier><identifier>DOI: 10.1016/j.amjmed.2020.06.003</identifier><language>eng</language><publisher>Elsevier Inc</publisher><ispartof>The American journal of medicine, 2020-10, Vol.133 (10), p.1229-1238</ispartof><rights>2020 Elsevier Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.amjmed.2020.06.003$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids></links><search><creatorcontrib>Lopes, Renato D.</creatorcontrib><creatorcontrib>Steffel, Jan</creatorcontrib><creatorcontrib>Di Fusco, Manuela</creatorcontrib><creatorcontrib>Keshishian, Allison</creatorcontrib><creatorcontrib>Luo, Xuemei</creatorcontrib><creatorcontrib>Li, Xiaoyan</creatorcontrib><creatorcontrib>Masseria, Cristina</creatorcontrib><creatorcontrib>Hamilton, Melissa</creatorcontrib><creatorcontrib>Friend, Keith</creatorcontrib><creatorcontrib>Gupta, Kiran</creatorcontrib><creatorcontrib>Mardekian, Jack</creatorcontrib><creatorcontrib>Pan, Xianying</creatorcontrib><creatorcontrib>Baser, Onur</creatorcontrib><creatorcontrib>Jones, W. Schuyler</creatorcontrib><title>Corrigendum to “Effectiveness and Safety of Oral Anticoagulants in Adults with Non-valvular Atrial Fibrillation Patients and Concomitant Coronary/Peripheral Artery Disease” American Journal of Medicine 131:09 (2018): 1074-1085.e4</title><title>The American journal of medicine</title><description>There were 33,269 apixaban-warfarin, 9,345 dabigatran-warfarin, and 42,156 rivaroxaban-warfarin matched pairs, with a median follow-up of 4-5 months. Compared with warfarin, apixaban was associated with lower rates of stroke/systemic embolism (hazard ratio [HR] 0.52; 95% confidence interval [95% CI], 0.43-0.62), major bleeding (HR 0.60; 95% CI, 0.55-0.66) and stroke/myocardial infarction/all-cause mortality (HR 0.70; 95%CI, 0.66-0.74); dabigatran was associated with lower rates of major bleeding (HR: 0.73; 95% CI, 0.62-0.85); dabigatran and rivaroxaban were associated with lower rates of stroke/myocardial infarction/all-cause mortality (HR 0.77; 95% CI, 0.69-0.86 and HR 0.81; 95% CI, 0.77-0.85, respectively). Rivaroxaban was associated with a lower rate of stroke/systemic embolism (HR 0.61; 95% CI, 0.53-0.71) and a higher rate of major bleeding (HR 1.10; 95%CI, 1.03-1.18) versus warfarin.</description><issn>0002-9343</issn><issn>1555-7162</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9UU1v1DAQjRBILIV_wMHHckhqx46T9IC02rZ8qNBKwNnyOuPWq8RebGfR3vpD4M_1xr9gluWMZGlmPPOePe8VxWtGK0aZPNtUetpMMFQ1rWlFZUUpf1IsWNM0Zctk_bRYUErrsueCPy9epLTBkvaNXBS_VyFGdwd-mCeSA3l8-HlpLZjsduAhJaL9QL5oC3lPgiU3UY9k6bMzQd_No_Y5EefJcphHzH64fE8-B1_u9LjDbiTLHB0irtw6unHU2QVPbjHAAXigXgVvwuQyMmEeg9dxf3YL0W3v4e9bMUPckwuXQCd4fPhFlhN2jfbkY5ijxxH81icYnHEeCOPsnPbktKase3NOGG1FyWjXVCBeFs-sHhO8-hdPim9Xl19X78vrm3cfVsvr0rC252XbibW1TBjTdLLlfTvwNWtrJqyQljW27wZptBhqvO_lWho2aNbUQkDTApc1PylOj7zbGL7PkLKaXDKA23sIc1K14HiYYBxHxXHUxJBSBKu20U2ogGJUHZxVG3V0Vh2cVVQqdBZhb48wwDV2DqJKBhU1KEJE59QQ3P8J_gCuTrDN</recordid><startdate>202010</startdate><enddate>202010</enddate><creator>Lopes, Renato D.</creator><creator>Steffel, Jan</creator><creator>Di Fusco, Manuela</creator><creator>Keshishian, Allison</creator><creator>Luo, Xuemei</creator><creator>Li, Xiaoyan</creator><creator>Masseria, Cristina</creator><creator>Hamilton, Melissa</creator><creator>Friend, Keith</creator><creator>Gupta, Kiran</creator><creator>Mardekian, Jack</creator><creator>Pan, Xianying</creator><creator>Baser, Onur</creator><creator>Jones, W. Schuyler</creator><general>Elsevier Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202010</creationdate><title>Corrigendum to “Effectiveness and Safety of Oral Anticoagulants in Adults with Non-valvular Atrial Fibrillation Patients and Concomitant Coronary/Peripheral Artery Disease” American Journal of Medicine 131:09 (2018): 1074-1085.e4</title><author>Lopes, Renato D. ; Steffel, Jan ; Di Fusco, Manuela ; Keshishian, Allison ; Luo, Xuemei ; Li, Xiaoyan ; Masseria, Cristina ; Hamilton, Melissa ; Friend, Keith ; Gupta, Kiran ; Mardekian, Jack ; Pan, Xianying ; Baser, Onur ; Jones, W. Schuyler</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1793-784bff14cc5867397d3b17214f46f15f98d6ca4d2d3b96b6c1da15244e57e3623</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lopes, Renato D.</creatorcontrib><creatorcontrib>Steffel, Jan</creatorcontrib><creatorcontrib>Di Fusco, Manuela</creatorcontrib><creatorcontrib>Keshishian, Allison</creatorcontrib><creatorcontrib>Luo, Xuemei</creatorcontrib><creatorcontrib>Li, Xiaoyan</creatorcontrib><creatorcontrib>Masseria, Cristina</creatorcontrib><creatorcontrib>Hamilton, Melissa</creatorcontrib><creatorcontrib>Friend, Keith</creatorcontrib><creatorcontrib>Gupta, Kiran</creatorcontrib><creatorcontrib>Mardekian, Jack</creatorcontrib><creatorcontrib>Pan, Xianying</creatorcontrib><creatorcontrib>Baser, Onur</creatorcontrib><creatorcontrib>Jones, W. Schuyler</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lopes, Renato D.</au><au>Steffel, Jan</au><au>Di Fusco, Manuela</au><au>Keshishian, Allison</au><au>Luo, Xuemei</au><au>Li, Xiaoyan</au><au>Masseria, Cristina</au><au>Hamilton, Melissa</au><au>Friend, Keith</au><au>Gupta, Kiran</au><au>Mardekian, Jack</au><au>Pan, Xianying</au><au>Baser, Onur</au><au>Jones, W. Schuyler</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Corrigendum to “Effectiveness and Safety of Oral Anticoagulants in Adults with Non-valvular Atrial Fibrillation Patients and Concomitant Coronary/Peripheral Artery Disease” American Journal of Medicine 131:09 (2018): 1074-1085.e4</atitle><jtitle>The American journal of medicine</jtitle><date>2020-10</date><risdate>2020</risdate><volume>133</volume><issue>10</issue><spage>1229</spage><epage>1238</epage><pages>1229-1238</pages><issn>0002-9343</issn><eissn>1555-7162</eissn><abstract>There were 33,269 apixaban-warfarin, 9,345 dabigatran-warfarin, and 42,156 rivaroxaban-warfarin matched pairs, with a median follow-up of 4-5 months. Compared with warfarin, apixaban was associated with lower rates of stroke/systemic embolism (hazard ratio [HR] 0.52; 95% confidence interval [95% CI], 0.43-0.62), major bleeding (HR 0.60; 95% CI, 0.55-0.66) and stroke/myocardial infarction/all-cause mortality (HR 0.70; 95%CI, 0.66-0.74); dabigatran was associated with lower rates of major bleeding (HR: 0.73; 95% CI, 0.62-0.85); dabigatran and rivaroxaban were associated with lower rates of stroke/myocardial infarction/all-cause mortality (HR 0.77; 95% CI, 0.69-0.86 and HR 0.81; 95% CI, 0.77-0.85, respectively). Rivaroxaban was associated with a lower rate of stroke/systemic embolism (HR 0.61; 95% CI, 0.53-0.71) and a higher rate of major bleeding (HR 1.10; 95%CI, 1.03-1.18) versus warfarin.</abstract><pub>Elsevier Inc</pub><doi>10.1016/j.amjmed.2020.06.003</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9343 |
| ispartof | The American journal of medicine, 2020-10, Vol.133 (10), p.1229-1238 |
| issn | 0002-9343 1555-7162 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2432431413 |
| source | Access via ScienceDirect (Elsevier) |
| title | Corrigendum to “Effectiveness and Safety of Oral Anticoagulants in Adults with Non-valvular Atrial Fibrillation Patients and Concomitant Coronary/Peripheral Artery Disease” American Journal of Medicine 131:09 (2018): 1074-1085.e4 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T17%3A10%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Corrigendum%20to%20%E2%80%9CEffectiveness%20and%20Safety%20of%20Oral%20Anticoagulants%20in%20Adults%20with%20Non-valvular%20Atrial%20Fibrillation%20Patients%20and%20Concomitant%20Coronary/Peripheral%20Artery%20Disease%E2%80%9D%20American%20Journal%20of%20Medicine%20131:09%20(2018):%201074-1085.e4&rft.jtitle=The%20American%20journal%20of%20medicine&rft.au=Lopes,%20Renato%20D.&rft.date=2020-10&rft.volume=133&rft.issue=10&rft.spage=1229&rft.epage=1238&rft.pages=1229-1238&rft.issn=0002-9343&rft.eissn=1555-7162&rft_id=info:doi/10.1016/j.amjmed.2020.06.003&rft_dat=%3Cproquest_cross%3E2432431413%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2432431413&rft_id=info:pmid/&rft_els_id=S0002934320305362&rfr_iscdi=true |